BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Congo declares its latest Ebola outbreak over, after 43 deaths - 25 Language Learning Applications
- 3China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- 4Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- 5Fundamental Home Items Each Animal person Needs
- Step by step instructions to Show Children the Significance of Appropriate Handshaking
- PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- The Main 20 Gaming Control center Ever
- Greece eyes migrant repatriation centres outside the EU
- 4 Energy-Proficient Clothes washers to Consider in 2024
- ‘We are the alternative’: Anti-Hamas Gaza militia tells BBC group is receiving international support
- Most loved Web-based feature: Which Stage Do You Like
- Monetary Freedom Guide: Plan Your Future
- Find the Advantages of Innovative Leisure activities: Supporting Creative mind and Self-Articulation
